AzurRx BioPharma, Inc. - FORM 10-K - EX-23 - CONSENTS OF EXPERTS AND COUNSEL - March 16, 2018

Attached files

file filename
EX-32.1 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - AzurRx BioPharma, Inc.ex32-1.htm
EX-31.2 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - AzurRx BioPharma, Inc.ex31-2.htm
EX-31.1 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - AzurRx BioPharma, Inc.ex31-1.htm
10-K - FORM 10-K - AzurRx BioPharma, Inc.azrx10k123117.htm
 
Exhibit 23
 
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
We hereby consent to the incorporation by reference in the Registration Statements on Form S-1 (File No. 333-219385), Form S-8 (File No. 333-220781) and Form S-3 (File No. 333-221275) of our report dated March 16, 2018, related to the consolidated financial statements of AzurRx BioPharma, Inc. as of December 31, 2017 and 2016 and for the years then ended, which appears in the Annual Report on Form 10-K of AzurRx BioPharma, Inc. for the year ended December 31, 2017. The report for AzurRx BioPharma, Inc. includes an explanatory paragraph about the existence of substantial doubt concerning its ability to continue as a going concern.
 
/s/ Mazars USA LLP
 
New York, New York
March 16, 2018
 
 
 
 

AzurRx BioPharma, Inc. Reports